#United States #Salt Lake City, Utah #glaucoma #Perfuse Therapeutics #PER-001

Overview

Perfuse Therapeutics, Inc. has made an impressive stride in the treatment of glaucoma with their innovative product, the PER-001 intravitreal implant. This pioneering biopharmaceutical company focuses on delivering cutting-edge therapies aimed at treating ischemia-induced ocular conditions. Recently, they announced that an oral presentation discussing the data from the PER-001 clinical trial will take place at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025, scheduled from May 4-8 in Salt Lake City, Utah.

The Significance of PER-001

PER-001 is a groundbreaking medication categorized as a first-in-class endothelin receptor antagonist. Endothelin is recognized as the strongest vasoconstrictor in the human body, playing a crucial role in inflammation and cell death within the ocular system. Given its function, increased levels of endothelin have been implicated in the pathology of glaucoma. The PER-001 implant is designed to provide sustained drug release through a convenient six-month dosing schedule, significantly improving patient compliance and therapeutic outcomes.

Presentation Details

The upcoming oral presentation will shed light on the findings from all patient cohorts who participated in the completed Phase 1/2a clinical trial. This study showcases data that extends beyond earlier revelations presented at the American Glaucoma Society Meeting. It emphasizes that PER-001 is not only well-tolerated but also holds promise as the first therapeutic intervention that modifies the disease’s progression.

Oral Presentation Details:

• - Title: "PER-001, an endothelin antagonist, increased optic nerve head blood flow with structural and functional improvements in patients with glaucoma"
• - Date & Time: Tuesday, May 6, 2025, from 2:45 PM to 3:00 PM MDT
• - Abstract Number: 3322
• - Session Title: Glaucoma Ocular blood flow and vascular pathophysiology
• - Location: Ballroom G
• - Presenter: Dr. Steven Mansberger, Chief of Ophthalmology and Director of Glaucoma Services at Legacy Devers Eye Institute.

Clinical Trial Insights

The Phase 1/2a clinical trial is a well-structured, multi-center study aimed at determining the safety and pharmacodynamics of PER-001. The first phase was an open-label trial that administered ascending doses of the implant to patients with varying degrees of glaucoma severity. Following this, the second phase introduced a randomized, sham-controlled approach to further assess the safety and therapeutic benefits of the treatment. With 24 weeks of follow-up for each patient after receiving the implant, the trial demonstrated significant promise in managing intraocular pressure while concurrently looking into structural changes in the optic nerve.

About Perfuse Therapeutics

Perfuse Therapeutics is dedicated to revolutionizing treatment methods for ocular diseases brought on by ischemic conditions. With a robust pipeline of innovative therapies and a focus on harnessing advanced drug delivery systems, the company aims to redefine standard care practices in ophthalmology. Headquartered in South San Francisco, California, and complemented by research and development facilities in Durham, North Carolina, they boast a team committed to making a global impact through transformative medical advancements.

For more details, visit Perfuse Therapeutics.

Conclusion

The announcement of an oral presentation at the ARVO Annual Meeting by Perfuse Therapeutics highlights not just their commitment to advancing glaucoma treatment but showcases the potential of PER-001 in creating a viable option for patients battling this debilitating condition. As the medical community eagerly anticipates these findings, the future of ocular therapeutics continues to look promising.